¼¼°èÀÇ À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå
Gene Therapy Clinical Trial Services
»óǰÄÚµå : 1774873
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 414 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀåÀº 2030³â±îÁö 19¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 12¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇè ¼­ºñ½º ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 19¾ï ´Þ·¯¿¡ À̸£°í, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.1%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÀÓ»ó½ÃÇè µðÀÚÀΣ¦Ç÷¡´×Àº CAGR 10.2%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 5¾ï 3,060¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼­ÇöóÀÌ£¦¹°·ù ¼­ºñ½º ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 9.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ¾à 3¾ï 1,750¸¸ ´Þ·¯, Áß±¹Àº CAGR 12.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀåÀº 2024³â¿¡ 3¾ï 1,750¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 4¾ï 630¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 12.9%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 4.0%¿Í 7.9%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.4%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇèÀÌ ±ÞÁõÇÏ´Â ÀÌÀ¯

À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇèÀº À¯ÀüÀÚ ÆíÁý ±â¼ú, ¹ÙÀÌ·¯½º º¤ÅÍ °³¹ß, ½Å±Ô À¯ÀüÀÚ Ä¡·á¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø µîÀÇ ¹ßÀüÀ¸·Î ÃÖ±Ù ±× ¾î´À ¶§º¸´Ù ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ Ä¡·á°¡ ½ÇÇèÀû ¿¬±¸¿¡¼­ ÀÓ»ó Àû¿ëÀ¸·Î ÀüȯµÊ¿¡ µû¶ó Àü¹® ÀÓ»ó½ÃÇè ¼­ºñ½º´Â ÀÌ·¯ÇÑ È¹±âÀûÀÎ Ä¡·á¹ýÀÇ ¾ÈÀü¼º, À¯È¿¼º ¹× Àå±âÀû ¿µÇâÀ» Æò°¡ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇèÀº ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ °æ·Î¸¦ È®¸³Çϰí, Åõ¿© ¿ä¹ýÀ» ÃÖÀûÈ­Çϸç, »ó¾÷Àû Ãâ½Ã Àü¿¡ ȯÀÚÀÇ ¾ÈÀüÀ» º¸ÀåÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

CRISPR ±â¹Ý À¯ÀüÀÚ ÆíÁý, AAV(¾Æµ¥³ëºÎ¼öü ¹ÙÀÌ·¯½º) º¤ÅÍ, ü¿Ü À¯ÀüÀÚ Ä¡·á ±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀ¸·Î ¿©·¯ Ä¡·á ºÐ¾ß¿¡ °ÉÃÄ ÀÓ»ó½ÃÇèÀÇ ¹üÀ§°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Èñ±Í À¯Àü¼º Áúȯ, À¯Àü¼º ´ë»çÁúȯ, °â»óÀûÇ÷±¸Áõ, º£Å¸ ÁöÁßÇØ ºóÇ÷°ú °°Àº Ç÷¾×ÁúȯÀº À¯ÀüÀÚ Ä¡·á ½ÃÇèÀÇ ÁÖ¿ä Ç¥Àû Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, CAR-T(Chimeric Antigen Receptor T-cell) Ä¡·á¿Í °°Àº À¯ÀüÀÚ º¯Çü ¼¼Æ÷Ä¡·áÁ¦°¡ Ç÷¾×¾Ç¼ºÁ¾¾ç Ä¡·á¿¡ À¯¸ÁÇÑ °á°ú¸¦ º¸À̸鼭 Á¾¾çÇÐÀÌ ÁÖ¿ä °ü½É ºÐ¾ß·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ È¯ÀÚ µî·Ï°ú ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Àü¹®ÀûÀÎ ÀÓ»ó½ÃÇè ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä´Â ±× ¾î´À ¶§º¸´Ù ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

À¯ÀüÀÚÄ¡·á ÀÓ»ó½ÃÇèÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â Ä¡·á ºÐ¾ß´Â?

À¯ÀüÀÚ Ä¡·á ºÐ¾ß´Â ¿©·¯ Áúȯ ¿µ¿ªÀ¸·Î È®´ëµÇ°í ÀÖÀ¸¸ç, °¢ ÁúȯÀº Àå±âÀûÀÎ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϱâ À§ÇØ ¾ö°ÝÇÑ ÀÓ»ó Æò°¡°¡ ÇÊ¿äÇÕ´Ï´Ù. Èñ±Í À¯Àü¼º ÁúȯÀº ¿©ÀüÈ÷ Áß¿äÇÑ ÃÊÁ¡À̸ç, µà¼¾Çü ±ÙÀÌ¿µ¾çÁõ(DMD), ô¼ö¼º ±ÙÀ§ÃàÁõ(SMA), ¸®¼ÒÁ» ÀúÀå Áúȯ µîÀÇ ÁúȯÀ» ´ë»óÀ¸·Î ÇÑ ÀÓ»ó½ÃÇèÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. À̵é ÀÓ»ó½ÃÇèÀÇ ´ëºÎºÐÀº °á¼Õ ¶Ç´Â °á¼ÕµÈ À¯Àü¹°ÁúÀ» º¸¿ÏÇÏ´Â ±â´ÉÀû À¯ÀüÀÚ¸¦ µµÀÔÇϱâ À§ÇØ ¹ÙÀÌ·¯½º ¶Ç´Â ºñ¹ÙÀÌ·¯½º¼º Àü´Þ ½Ã½ºÅÛÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù.

¾Ï ºÐ¾ß¿¡¼­´Â À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇèÀ» ÅëÇØ ȯÀÚÀÇ ¸é¿ª¼¼Æ÷¸¦ º¯Çü½ÃÄÑ ¾Ï°ú ½Î¿ì´Â ´É·ÂÀ» Çâ»ó½ÃŰ´Â ¸é¿ªÄ¡·á Á¢±Ù¹ýÀ» ¹ßÀü½Ã۰í ÀÖÀ¸¸ç, CAR-T ¼¼Æ÷ Ä¡·á´Â ¾Ï¼¼Æ÷¸¦ ÀνÄÇÏ°í ÆÄ±«Çϵµ·Ï T¼¼Æ÷¸¦ À¯ÀüÀûÀ¸·Î ÀçÇÁ·Î±×·¡¹ÖÇÏ¿© ¹éÇ÷º´, ¸²ÇÁÁ¾, ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·á¿¡ ȹ±âÀûÀÎ ÁøÀüÀ» °¡Á®¿Ô½À´Ï´Ù. ȹ±âÀûÀÎ ÁøÀüÀ» °¡Á®¿Ô½À´Ï´Ù. ÆÄŲ½¼º´, ¾ËÃ÷ÇÏÀ̸Ӻ´, ÇåÆÃÅϺ´°ú °°Àº ½Å°æÁúȯµµ À¯ÀüÀÚ Ä¡·á ½ÃÇèÀÇ ÀáÀçÀû Ÿ°ÙÀ¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ½Å°æ º¸È£ À¯ÀüÀÚ º¯Çü¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. Ä¡·áÀÇ ÆøÀÌ ³Ð¾îÁü¿¡ µû¶ó À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇèÀº ½ÉÇ÷°ü, ¾È°ú, ÀÚ°¡¸é¿ªÁúȯ Ä¡·á·Î È®´ëµÇ°í ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇè ¼­ºñ½ºÀÇ Ãֽбâ¼ú Çõ½ÅÀº ¹«¾ùÀΰ¡?

À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇè ¹æ¹ý·ÐÀÇ ¹ßÀüÀ¸·Î ÀÓ»ó½ÃÇè ¼³°è, ȯÀÚ ¸ðÁý, ±ÔÁ¦ Áؼö µîÀÌ Å©°Ô °³¼±µÇ¾ú½À´Ï´Ù. °¡Àå Áß¿äÇÑ Çõ½Å Áß Çϳª´Â AI ±â¹Ý ºÐ¼®À» »ç¿ëÇÏ¿© ȯÀÚ ¼±ÅÃÀ» °£¼ÒÈ­Çϰí À¯ÀüÀÚ Ä¡·áÀÇ ÇýÅÃÀ» °¡Àå ¸¹ÀÌ ¹ÞÀ» °¡´É¼ºÀÌ °¡Àå ³ôÀº ȯÀÚ¸¦ ÀÓ»ó½ÃÇè¿¡ µî·ÏÇÏ´Â °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, AI ±â¹Ý µ¥ÀÌÅÍ °ü¸® Ç÷§ÆûÀº ÀÓ»ó½ÃÇè ¸ð´ÏÅ͸µÀ» °³¼±Çϰí ȯÀÚÀÇ ¹ÝÀÀ°ú ºÎÀÛ¿ëÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

¶ÇÇÑ, ºÐ»êÇü ÀÓ»ó½ÃÇè ¸ðµ¨ÀÇ °³¹ß·Î ȯÀÚ Á¢±Ù¼ºÀÌ Çâ»óµÇ¾î Âü°¡ÀÚµéÀº µðÁöÅÐ Çコ Ç÷§ÆûÀ» ÅëÇØ ¿ø°ÝÀ¸·Î ƯÁ¤ Æò°¡¸¦ ¹ÞÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. À¯ÀüÀÚ ¹× ºÐÀÚ ÇÁ·ÎÆÄÀϸµÀ» ÅëÇØ ¹ÝÀÀÀÚ¸¦ ½Äº°ÇÏ´Â ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý ÀÓ»ó½ÃÇèÀÇ µîÀåÀº ÀÓ»ó½ÃÇèÀÇ È¿À²¼ºÀ» Çâ»ó½ÃÄÑ º¯¼ö¸¦ ÁÙÀÌ°í ¼º°ø·üÀ» ³ôÀÓÀ¸·Î½á ÀÓ»ó½ÃÇèÀÇ È¿À²À» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, FDA ¹× EMA¿Í °°Àº ±ÔÁ¦ ±â°üÀº À¯¸ÁÇÑ À¯ÀüÀÚ Ä¡·áÁ¦¿¡ ´ëÇÑ ½Å¼ÓÇÑ ½ÂÀÎ °æ·Î¸¦ µµÀÔÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÓ»ó½ÃÇè ¼­ºñ½º¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº À¯ÀüÀÚÄ¡·áÁ¦ ÀÓ»ó½ÃÇè ÇÁ·Î¼¼½º¸¦ ÃÖÀûÈ­ÇÏ°í ¿¬±¸ºÎÅÍ »ó¾÷È­±îÁö °É¸®´Â ½Ã°£À» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇè ¼­ºñ½º ½ÃÀåÀÇ ¼ºÀåÀº À¯ÀüÀÚ ±â¹Ý Ä¡·á¹ý¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø, ÀÓ»ó½ÃÇè ¼³°èÀÇ ±â¼úÀû Áøº¸ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷µéÀº À¯ÀüÀÚ Ä¡·á ¿¬±¸¿¡ ¸·´ëÇÑ ÀÚ¿øÀ» ÅõÀÔÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°èÀûÀ¸·Î ÀÓ»ó½ÃÇèÀÇ ±ÞÁõÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. Çϰí ÀÖ½À´Ï´Ù.

À¯ÀüÀÚÄ¡·áÁ¦ ÀÓ»ó½ÃÇèÀ» Àü¹®À¸·Î ÇÏ´Â ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO)ÀÇ È®´ëµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌµé ±â°üÀº ±ÔÁ¦ ´ç±¹ ´ëÀÀ, ȯÀÚ ¸ðÁý, À¯ÀüÀÚ ±â¹Ý Ä¡·áÁ¦¿¡ ´ëÇÑ ¿ì¼öÀǾàǰ Á¦Á¶ ¹× ǰÁú°ü¸®±âÁØ(GMP) Áؼö¿¡ ´ëÇÑ Àü¹®¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, º¤ÅÍ Á¦Á¶ ¹× À¯ÀüÀÚ µµÀÔ ½Ã½ºÅÛÀÇ ¹ßÀüÀ¸·Î ÀÓ»ó½ÃÇèÀÇ È®À强°ú È¿À²¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ Ä¡·á°¡ Áúº´ Ä¡·á¿¡ Çõ¸íÀ» °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµÇ´Â °¡¿îµ¥, Àü¹® ÀÓ»ó½ÃÇè ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä´Â È®´ëµÇ¾î Á¤¹ÐÀÇ·á¿Í À¯ÀüÀÚ Çõ½ÅÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

¼­ºñ½º(ÀÓ»ó½ÃÇè ¼³°è ¹× °èȹ, °ø±Þ ¹× ¹°·ù ¼­ºñ½º, ±ÔÁ¦ ¼­ºñ½º, µ¥ÀÌÅÍ °ü¸® ¹× »ý¹° Åë°è, »çÀÌÆ® °ü¸® ¹× ¸ð´ÏÅ͸µ, ±âŸ À¯ÀüÀÚ Ä¡·á ÀÓ»ó½ÃÇè ¼­ºñ½º); Ä¡·á ºÐ¾ß(Á¾¾çÇÐ, Ç÷¾×ÇÐ, ³»ºÐºñ/´ë»ç Àå¾Ö, ±Ù°ñ°Ý°è Áúȯ, ½ÉÇ÷°ü Áúȯ, ½Å°æÇÐ Áúȯ, °¨¿°¼º Áúȯ, ¾È°ú, ¸é¿ªÇÐ, ±âŸ Ä¡·á ºÐ¾ß); ÃÖÁ¾ »ç¿ëÀÚ(Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷ ÃÖÁ¾ »ç¿ëÀÚ, ¼öŹ ¿¬±¸ ±â°ü ÃÖÁ¾ »ç¿ëÀÚ, Çмú ¹× ¿¬±¸ ±â°ü ÃÖÁ¾ »ç¿ëÀÚ, ±âŸ ÃÖÁ¾ »ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Gene Therapy Clinical Trial Services Market to Reach US$1.9 Billion by 2030

The global market for Gene Therapy Clinical Trial Services estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Clinical Trial Design & Planning, one of the segments analyzed in the report, is expected to record a 10.2% CAGR and reach US$530.6 Million by the end of the analysis period. Growth in the Supply & Logistics Services segment is estimated at 9.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$317.5 Million While China is Forecast to Grow at 12.9% CAGR

The Gene Therapy Clinical Trial Services market in the U.S. is estimated at US$317.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$406.3 Million by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Gene Therapy Clinical Trial Services Market - Key Trends & Drivers Summarized

Why Are Gene Therapy Clinical Trials Expanding Rapidly?

Gene therapy clinical trials have witnessed unprecedented growth in recent years, driven by advancements in gene-editing technologies, viral vector development, and regulatory support for novel genetic treatments. As gene therapy moves from experimental research to clinical application, specialized clinical trial services are playing a crucial role in evaluating the safety, efficacy, and long-term impact of these groundbreaking therapies. Clinical trials are essential for establishing regulatory approval pathways, optimizing dosing regimens, and ensuring patient safety before commercial deployment.

The rapid development of CRISPR-based gene editing, AAV (Adeno-Associated Virus) vectors, and ex vivo gene therapy techniques has expanded the scope of clinical trials across multiple therapeutic areas. Rare genetic disorders, inherited metabolic diseases, and hematological conditions such as sickle cell disease and beta-thalassemia are among the primary targets of gene therapy trials. Additionally, oncology has emerged as a major focus area, with gene-modified cell therapies such as CAR-T (Chimeric Antigen Receptor T-cell) therapy demonstrating promising results in treating hematologic malignancies. With increasing patient enrollment and investment in gene therapy trials, the demand for specialized clinical trial services is at an all-time high.

Which Therapeutic Areas Are Driving the Growth of Gene Therapy Clinical Trials?

The field of gene therapy is expanding into multiple disease areas, each requiring rigorous clinical evaluation to ensure long-term safety and effectiveness. Rare genetic disorders remain a significant focus, with clinical trials targeting conditions such as Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and lysosomal storage diseases. Many of these trials leverage viral and non-viral delivery systems to introduce functional genes that compensate for defective or missing genetic material.

In oncology, gene therapy clinical trials are advancing immunotherapy approaches that modify a patient’s immune cells to enhance cancer-fighting capabilities. CAR-T cell therapy, which involves genetically reprogramming T cells to recognize and destroy cancer cells, has led to breakthroughs in leukemia, lymphoma, and multiple myeloma treatment. Neurological disorders such as Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease are also emerging as potential targets for gene therapy trials, with research focusing on neuroprotective gene modifications. As the therapeutic landscape broadens, gene therapy clinical trials are expanding into cardiovascular, ophthalmic, and autoimmune disease treatments.

What Are the Latest Innovations in Gene Therapy Clinical Trial Services?

Advancements in gene therapy trial methodologies have significantly improved trial design, patient recruitment, and regulatory compliance. One of the most important innovations is the use of AI-driven analytics to streamline patient selection, ensuring that clinical trials enroll individuals with the highest likelihood of benefiting from gene therapy. AI-powered data management platforms are also improving trial monitoring, enabling real-time tracking of patient responses and adverse events.

Additionally, the development of decentralized clinical trial models has increased patient accessibility, allowing participants to undergo certain assessments remotely through digital health platforms. The rise of biomarker-driven trials, which use genetic and molecular profiling to identify responders, has enhanced trial efficiency by reducing variability and increasing success rates. Furthermore, regulatory agencies such as the FDA and EMA have introduced accelerated approval pathways for promising gene therapies, leading to increased investment in clinical trial services. These advancements are optimizing the gene therapy trial process, accelerating the timeline from research to commercialization.

What Factors Are Fueling the Growth of the Gene Therapy Clinical Trial Services Market?

The growth in the gene therapy clinical trial services market is driven by several factors, including rising investment in gene-based treatments, regulatory support for innovative therapies, and technological advancements in clinical trial design. Pharmaceutical and biotech companies are dedicating substantial resources to gene therapy research, leading to a surge in trial activity worldwide. The success of FDA-approved gene therapies, such as Luxturna and Zolgensma, has further validated the potential of gene therapy, encouraging increased clinical trial participation.

The expansion of contract research organizations (CROs) specializing in gene therapy trials has also contributed to market growth. These organizations provide expertise in regulatory navigation, patient recruitment, and compliance with Good Manufacturing Practices (GMP) for gene-based treatments. Additionally, advancements in vector manufacturing and gene delivery systems have improved trial scalability and efficiency. With gene therapy expected to revolutionize disease treatment, the demand for specialized clinical trial services is projected to grow, shaping the future of precision medicine and genetic innovation.

SCOPE OF STUDY:

The report analyzes the Gene Therapy Clinical Trial Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Services (Clinical Trial Design & Planning, Supply & Logistics Services, Regulatory Services, Data Management & Biostatistics, Site Management & Monitoring, Other Gene Therapy Clinical Trial Services); Therapeutic Area (Oncology, Hematology, Endocrine / Metabolic Disorders, Musculoskeletal Diseases, Cardiovascular Diseases, Neurology Disorders, Infectious Diseases, Ophthalmology, Immunology, Other Therapeutic Areas); End-User (Pharma & Biotech Companies End-User, Contract Research Organizations End-User, Academic & Research Institutes End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â